Home > Papers

 
 
Teriparatide in the treatment of osteoradionecrosis of the jaws: a controlled clinical trial
Hao Nie,Weihong Wang *,Biao Xu,Jingyi Li,Yu Liu,Yemei Qian
Department of Oral and Maxillofacial Surgery, Affiliated Stomatology Hospital of Kunming Medical University, Kunming 650106, China;Department of Oral and Maxillofacial Surgery, Affiliated Stomatology Hospital of Kunming Medical University, Kunming 650106, China;Department of Oral and Maxillofacial Surgery, Affiliated Stomatology Hospital of Kunming Medical University, Kunming 650106, China;Department of Oral and Maxillofacial Surgery, Affiliated Stomatology Hospital of Kunming Medical University, Kunming 650106, China;Department of Oral and Maxillofacial Surgery, Affiliated Stomatology Hospital of Kunming Medical University, Kunming 650106, China;Department of Oral and Maxillofacial Surgery, Affiliated Stomatology Hospital of Kunming Medical University, Kunming 650106, China
*Correspondence author
#Submitted by
Subject:
Funding: Medicine Leading Talent of Yunnan Province Health Care Committee (No.No.L-201801), Yunnan Provincial Clinical Medical Research Centre for Oral Diseases Research Fund)
Opened online:20 February 2023
Accepted by: none
Citation: Hao Nie,Weihong Wang,Biao Xu.Teriparatide in the treatment of osteoradionecrosis of the jaws: a controlled clinical trial[OL]. [20 February 2023] http://en.paper.edu.cn/en_releasepaper/content/4759022
 
 
Objective: To investigate the clinical therapeutic effect of teriparatide on osteoradionecrosis of the jaws (ORNJ). Materials and Methods: From May 2021 to November 2022, altogether 17 patients with ORNJ who consulted were divided into teriparatide and control groups. Following basic treatment including lesion removal, teriparatide group received subcutaneous administration of the drug (20ug/d) for two months, whereas control group received basic treatment only (including lesion excision.). Finally, patients underwent wound healing and jaw bone regeneration in the region of necrotic bone under observation. Results: There were seven patients in control group and ten in teriparatide group. In the course of treatment, two patients in teriparatide group withdrew from the research due to drug allergy and stroke, while the remaining eight experienced no side effects. A significant amount of new bone regeneration was observed in the region of dead bone in five patients in the teriparatide group, and their healing rate (37.5%) was higher than that of control group (14.2%) (P<0.001). Conclusion: Teriparatide can improve wound healing and new bone regeneration in patients with ORNJ after the removal of moribund bone from ORNJ.
Keywords:Osteoradionecrosis of the jaws(ORNJ); Teriparatide; Medication-induced jaw osteonecrosis (MRONJ)
 
 
 

For this paper

  • PDF (0B)
  • ● Revision 0   
  • ● Print this paper
  • ● Recommend this paper to a friend
  • ● Add to my favorite list

    Saved Papers

    Please enter a name for this paper to be shown in your personalized Saved Papers list

Tags

Add yours

Related Papers

Statistics

PDF Downloaded 25
Bookmarked 0
Recommend 0
Comments Array
Submit your papers